The Prognostic Value of Big Endothelin-1 in More Than 2,300 Patients With Heart Failure Enrolled in the Valsartan Heart Failure Trial (Val-HeFT)
- 30 June 2006
- journal article
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 12 (5) , 375-380
- https://doi.org/10.1016/j.cardfail.2006.02.013
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Valsartan Heart Failure Trial (Val-HeFT)American Heart Journal, 2005
- Mechanisms of elevated plasma endothelin-1 in CHF: congestion increases pulmonary synthesis and secretion of endothelin-1Cardiovascular Research, 2004
- A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart FailureNew England Journal of Medicine, 2001
- Prognostic value of neurohormonal activation and cardiopulmonary exercise testing in patients with chronic heart failureThe American Journal of Cardiology, 2000
- Mechanisms of Big Endothelin-1–Induced Diuresis and NatriuresisHypertension, 2000
- ET B Receptor Blockade Potentiates the Pressor Response to Big Endothelin-1 But Not Big Endothelin-2 in the Anesthetized RabbitHypertension, 2000
- Receptor- and non-receptor-mediated clearance of bigendothelin and endothelin-1Journal Of Hypertension, 2000
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999
- Prognostic value of plasma soluble intercellular adhesion molecule-1 and endothelin-1 concentration in patients with chronic congestive heart failureThe American Journal of Cardiology, 1995
- Plasma big endothelin-1 concentrations in congestive heart failure patients with or without systemic hypertensionThe American Journal of Cardiology, 1993